TASK ORDER 16: USE OF INHALED HYALURONAN IN PATIENTS WITH SEVERE COVID-19

任务令 16：在重症 COVID-19 患者中使用吸入透明质酸

基本信息

批准号：
10474789
负责人：
TAHARAT KHAN
金额：
$ 22.52万
依托单位：
SOCIAL AND SCIENTIFIC SYSTEMS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2022-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10474789
关键词：
2019-nCoV Acute Respiratory Distress Syndrome Adult Adverse event Affect Animal Experiments Anti-Inflammatory Agents Antiviral Agents COVID-19 COVID-19 treatment Cell Culture Techniques Cells Clinical Contracts Control Groups Coronavirus Infections Disease Epithelial Cells Extracellular Matrix Glycosaminoglycans Hospitals Hyaluronan Immune response Incidence Inflammation Inhalation Inpatients Intervention Intervention Studies Intubation Investigation Laboratories Length of Stay Life Lung Lung diseases Outcome Oxygen Oxygen Therapy Care Patients Placebo Control Placebos Property Randomized Recovery Reporting Respiratory Failure Role Rome SARS-CoV-2 infection Safety Serious Adverse Event Steroids Suspensions Teaching Hospitals Therapeutic Time Toxicant exposure Virus Diseases arm clinical efficacy efficacy evaluation epithelial injury inflammatory marker lung injury lung repair prevent pulmonary function repaired respiratory severe COVID-19 sugar ventilation virology ward

项目摘要

COVID-19 is a potentially life-threatening infection by the coronavirus SARS-CoV2, which infects respiratory cells and induces epithelial injury, causing susceptible patients to develop adult respiratory distress syndrome (ARDS). ARDS leads to significant inflammation and accumulation of extracellular matrix (ECM), including hyaluronan (HA), a glycosaminoglycan sugar and abundant component of the lung ECM. HA is a powerful modulator of lung injury, inflammation and repair and is found in the airway lumen overlaying ciliated epithelial cells. Airway HA expression is induced by epithelial injury, including viral infection and recent reports highlight increased HA concentration in COVID-19 affected lungs as well. In cell culture and animal experiments we had found that therapeutic HA inhalation protects against SARS-CoV-2 infection. this study we explored the therapeutic role of HA COVID19-induced lung disease in patients with established moderate disease (admitted to hospital, in need for oxygen therapy). Specifically, we questioned whether inhaled HA may promote recovery from COVID19, since HA has antiviral, anti-inflammatory and pro-lung repair properties and ameliorates lung injury after a number of infectious and toxic exposures. We contracted with the Rome facility and initiated a study of inhaled HA (at least 10 days) or placebo. The outcomes were need for oxygen, and length of hospital stay.

Covid-19是冠状病毒SARS-COV2的潜在威胁生命的感染，它感染了呼吸细胞并诱导上皮损伤，导致易感患者发展成人呼吸窘迫综合征（ARDS）。 ARDS导致细胞外基质（ECM）的显着炎症和积累，包括透明质酸（HA），糖胺聚糖糖和肺ECM的丰富成分。 HA是肺损伤，炎症和修复的强大调节剂，在覆盖纤毛上皮细胞的气道管腔中发现。气道HA的表达是由上皮损伤引起的，包括病毒感染，最近的报道也强调了COVID-19受影响的肺的HA浓度增加。在细胞培养和动物实验中，我们发现治疗性吸入可防止SARS-COV-2感染。这项研究探讨了HA Covid19诱导的肺疾病在中度疾病患者中的治疗作用（入院，需要氧气治疗）。具体而言，我们质疑吸入的HA是否可以促进Covid19的恢复，因为HA具有抗病毒，抗炎和促肺修复特性，并在许多感染性和有毒的暴露后改善了肺损伤。我们与罗马设施签约，并开始了对吸入HA（至少10天）或安慰剂的研究。结果是需要氧气和住院时间。